The Question Everyone Is Asking
This week I attended a caregiver conference where a neurologist who has been overseeing Leqembi infusions at a memory care center took the stage for the keynote. The room was full of caregivers, professionals, and people living with early-stage Alzheimer's disease. And the question that kept surfacing, in different forms, was the same one I hear everywhere right now.
What does this new drug actually mean for us?
It is a fair question. The headlines have been significant. The FDA has approved a new way to take Leqembi, the first disease-modifying treatment for early Alzheimer's disease to receive approval in the United States. And while the clinical language around this approval is important, it is not written for the person who is managing a full day of caregiving and trying to figure out whether any of this changes their Tuesday morning.
So let me try to give you a straight answer.
What Actually Changed
Leqembi, known generically as lecanemab, was originally approved in 2023 as a biweekly intravenous infusion for people with mild cognitive impairment or mild dementia due to Alzheimer's disease. That meant clinic visits, IV lines, monitoring, and hours out of the week, every two weeks, for months.
What the FDA has now approved is an at-home injectable maintenance option called Leqembi IQLIK, pronounced eye-CLICK. It is an autoinjector, similar in concept to the devices used for diabetes or rheumatoid arthritis. The injection takes approximately fifteen seconds. It is designed to be administered at home, once a week, after the person has completed the initial course of IV infusions.
That initial IV phase still happens in a clinical setting. The at-home option is a maintenance phase, meaning it is for people who have already completed that first round of treatment and are ready to transition to ongoing dosing at home.
There is also a separate application currently under FDA review that would allow the starting doses to be administered at home as well. That decision was originally expected by May 24, 2026, but the FDA extended its review by three months this week, moving the new decision date to August 24, 2026. The FDA requested additional information from Eisai, though it has not raised concerns about whether the formulation will ultimately be approved. For now, the starting phase still requires clinic-based infusions.
Who Qualifies and What the Process Looks Like
This is where caregivers need the most clarity, because the headlines do not always tell this part of the story.
Leqembi is approved for early-stage Alzheimer's disease only. That means mild cognitive impairment or mild dementia. It is not approved for middle-stage or late-stage dementia. To qualify, a person must have confirmation of amyloid plaques in the brain through either a PET scan or a spinal fluid test. Not everyone with an Alzheimer's diagnosis has had this testing, and not every diagnosis will qualify.
If the person you are supporting is already in the mild stage, has a confirmed diagnosis through their neurologist, and has not yet explored whether they might be eligible, that conversation starts with their physician. The neurologist at the conference emphasized that early and accurate diagnosis is the critical first step, because the window of eligibility for this treatment is specific to the early stage.
If the person is already receiving Leqembi through IV infusions and has completed the initial eighteen-month course, the at-home injectable option may now be available to them. That conversation also starts with their treating physician, who will determine whether the transition is appropriate based on their response to treatment and any side effect monitoring that is still required.
One thing the neurologist made clear in her keynote: the drug does not eliminate the need for ongoing clinical oversight. Even on the at-home injectable, monitoring continues. The logistical burden changes. It does not disappear.
What It Does Not Change
This is the part I want to sit with for a moment, because I think it is the most important thing caregivers need to hear right now.
Leqembi is a disease-modifying treatment. That means it works to slow the progression of the underlying disease in the early stage. In clinical trials, it demonstrated a meaningful slowing of cognitive decline compared to a placebo. That is genuinely significant, and it represents a different kind of progress than anything that has come before it in Alzheimer's care.
But slowing progression is not the same as stopping it. And it is not the same as reversing it. The people in the clinical trials still experienced decline. They still needed caregiving. The families supporting them still sat at tables navigating the same spoke failures we have been talking about in this series.
The approval of an at-home injectable reduces one logistical burden. Fewer clinic visits, more flexibility, less time sitting through infusions. For caregivers who have been building their weeks around those appointments, that is a meaningful change.
It does not change the sensory processing that makes a white plate on a white tablecloth invisible to the brain. It does not fix the initiation failure that keeps a person from picking up a fork. It does not repair the Environmental Spoke when the television is too loud or the Emotional Spoke when the caregiver enters the room already exhausted.
The drug and the caregiving are two parallel tracks. Right now, both matter.
What This Means If You Are in the Middle of It
If the person you are supporting is in the early stage and you have not yet had a conversation with their neurologist about whether they might be eligible for this treatment, this is a good week to make that call. Ask specifically about amyloid confirmation and eligibility for disease-modifying treatment. Bring someone with you to the appointment if you can, because these conversations are dense and the details matter.
If the person is already in the middle or late stage of dementia, this particular treatment is not where your energy belongs right now. Your work is at the table, in the room, in the routine. That work is as clinical and as important as anything happening in a research setting, even when it does not feel that way.
And if you are a professional supporting families through this, the question you are most likely to hear right now is some version of: should my person be on this drug? The most helpful thing you can do is help them bring a clear list of questions to their neurologist, understand the eligibility criteria, and manage the expectation that this is one piece of a very large and ongoing care picture.
The Bigger Picture
The neurologist who spoke this week said something that stayed with me. She said that the approval of at-home treatment is meaningful not just because it reduces clinic visits, but because it signals a shift in how we think about where Alzheimer's care happens. For decades, meaningful treatment has been something that happened in a clinical setting, under clinical supervision, with the caregiver as a bystander. Bringing any part of that into the home changes the relationship between the treatment and the daily life of the person receiving it.
That is worth paying attention to.
At the same time, the daily life piece, the meals, the routines, the environment, the emotional tone of the room, has always been where caregivers live. That has not changed. And in many ways, the growing recognition that treatment belongs in the home is also a recognition that what caregivers do every day has always been a form of treatment too.
You have been practicing precision medicine at the kitchen table for years. It just has not always been called that.
If you are navigating early-stage dementia and want a framework for understanding what is happening day to day, my free Quick-Start Guide for Caregivers is a good place to start. And if you are already deep in the daily caregiving work and mealtimes have become the hardest part of your day, Calmer Meals in 5 Days is a $15 mini-course built around the Wheel of Function Framework™ that gives you five practical strategies, one per day, starting at your very next meal.
Disclaimer
The information provided in this post is for educational purposes only and should not be considered medical advice. Always consult with a physician or licensed healthcare provider before making any decisions about treatment. Every individual's situation is different, and professional guidance is essential.
Notes
- BrightFocus Foundation. (2026). Expanding the Alzheimer's treatment landscape: A 2026 forecast. https://www.brightfocus.org/resource/expanding-the-alzheimers-treatment-landscape-a-2026-forecast/
- BrightFocus Foundation. (2025). FDA approves at-home injectable Leqembi for Alzheimer's. https://www.brightfocus.org/news/fda-approves-at-home-injectable-leqembi-for-alzheimers/
- Biogen Inc. (2026, January 25). FDA accepts LEQEMBI IQLIK supplemental biologics license application as a subcutaneous starting dose for the treatment of early Alzheimer's disease under priority review. https://investors.biogen.com/news-releases/news-release-details/fda-accepts-leqembir-iqliktm-lecanemab-irmb-supplemental
- Biogen Inc. (2026, May 7). Update on FDA priority review of LEQEMBI IQLIK subcutaneous injection as a starting dose for early Alzheimer's disease. https://investors.biogen.com/news-releases/news-release-details/update-fda-priority-review-leqembir-iqliktm-lecanemab-irmb
- NeurologyLive. (2026). FDA approves lecanemab autoinjector, marking first at-home treatment for Alzheimer disease. https://www.neurologylive.com/view/fda-approves-lecanemab-autoinjector-first-at-home-treatment-alzheimer-disease
- AllSci. (2026, May 7). FDA extends Leqembi Iqlik review to August 2026. https://allsci.com/news/approvals/fda-adds-3-months-to-review-of-eisais-leqembi-iqlik-subcutaneous-formulation-for-early-alzheimers/
Want to keep figuring this out together?
Subscribe to Finding Our Way in Dementia Care and get honest stories, helpful tips, and gentle support delivered to your inbox every week. Just real talk, grounded care, and space to breathe.
Subscribe to Finding Our Way in Dementia Care and get honest stories, helpful tips, and gentle support delivered to your inbox every week. Just real talk, grounded care, and space to breathe.
Kind truth. Clear steps. Warm guide.
0 Comments